These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 1540595)

  • 1. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation.
    Veldscholte J; Berrevoets CA; Brinkmann AO; Grootegoed JA; Mulder E
    Biochemistry; 1992 Mar; 31(8):2393-9. PubMed ID: 1540595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
    Berrevoets CA; Veldscholte J; Mulder E
    J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the human prostatic cancer cell line LNCaP.
    Veldscholte J; Berrevoets CA; Mulder E
    J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):341-6. PubMed ID: 8043498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
    Veldscholte J; Berrevoets CA; Ris-Stalpers C; Kuiper GG; Jenster G; Trapman J; Brinkmann AO; Mulder E
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):665-9. PubMed ID: 1562539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation.
    Kokontis J; Ito K; Hiipakka RA; Liao S
    Receptor; 1991; 1(4):271-9. PubMed ID: 1668832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.
    Veldscholte J; Ris-Stalpers C; Kuiper GG; Jenster G; Berrevoets C; Claassen E; van Rooij HC; Trapman J; Brinkmann AO; Mulder E
    Biochem Biophys Res Commun; 1990 Dec; 173(2):534-40. PubMed ID: 2260966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
    Warriar N; Pagé N; Koutsilieris M; Govindan MV
    Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens.
    Kuil CW; Mulder E
    Endocrinology; 1996 May; 137(5):1870-7. PubMed ID: 8612526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
    Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
    Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors.
    Veldscholte J; Berrevoets CA; Zegers ND; van der Kwast TH; Grootegoed JA; Mulder E
    Biochemistry; 1992 Aug; 31(32):7422-30. PubMed ID: 1510931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.
    Song LN; Coghlan M; Gelmann EP
    Mol Endocrinol; 2004 Jan; 18(1):70-85. PubMed ID: 14593076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
    Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
    Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H
    Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: inhibition of cat expression by anti-androgens.
    Fuhrmann U; Bengtson C; Repenthin G; Schillinger E
    J Steroid Biochem Mol Biol; 1992 Sep; 42(8):787-93. PubMed ID: 1326316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
    Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
    Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.
    Kemppainen JA; Lane MV; Sar M; Wilson EM
    J Biol Chem; 1992 Jan; 267(2):968-74. PubMed ID: 1730684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.